Cargando…

Adalimumab/infliximab: Lower serologic response: 6 case reports

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008658/ http://dx.doi.org/10.1007/s40278-022-13165-9

Ejemplares similares

Adalimumab/golimumab/infliximab: SARS-CoV-2 pneumonia: 3 case reports
Publicado: (2021)

Failure of response to combination therapy of adalimumab and infliximab in a recalcitrant patient of severe psoriasis and major thalassemia: A case report
por: Goldust, Mohamad, et al.
Publicado: (2020)

Adalimumab for orbital myositis in a patient with Crohn’s disease who discontinued infliximab: a case report and review of the literature
por: Verma, Sanam, et al.
Publicado: (2013)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
por: Suzuki, Taketo, et al.
Publicado: (2019)

Multicentric reticulohistiocytosis: A case report with response to adalimumab
por: Kim, Shirley, et al.
Publicado: (2020)

Adalimumab: Cutaneous leishmaniasis: case report
Publicado: (2022)

Infliximab: Autoimmune hepatitis: case report
Publicado: (2022)

Infliximab: Lack of efficacy: case report
Publicado: (2021)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis
por: Mase, Oliver, et al.
Publicado: (2023)

Adalimumab: COVID-19 infection: case report
Publicado: (2022)

Adalimumab: COVID-19 and glomerulosclerosis: case report
Publicado: (2021)

Infliximab: COVID-19 pneumonia: case report
Publicado: (2020)

Adalimumab for Corticosteroid and Infliximab-Resistant Immune Reconstitution Inflammatory Syndrome in the Setting of TB/HIV Coinfection
por: Lwin, Nilar, et al.
Publicado: (2018)

Adalimumab/methotrexate: COVID-19 infection: case report
Publicado: (2020)

Adalimumab: Pauci-immune crescentric glomerulonephritis: case report
Publicado: (2021)

Adalimumab/prednisone: Mycobacterium chelonae infection: case report
Publicado: (2021)

Adalimumab/vedolizumab: Gastroparesis and COVID infection: case report
Publicado: (2021)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
por: Song, Christine H, et al.
Publicado: (2012)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Response of Fibroblastic Rheumatism to Infliximab
por: Romiti, Ricardo, et al.
Publicado: (2009)

Adalimumab-Responsive Refractory Sarcoidosis Following Multiple Eyebrow Tattoos: A Case Report
por: Mirzaei, Alireza, et al.
Publicado: (2017)

Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study
por: Ortea, Ignacio, et al.
Publicado: (2016)

Methylprednisolone/infliximab/anakinra: Lack of efficacy: case report
Publicado: (2021)

Accelerated Infliximab Induction for Severe Lower Gastrointestinal Bleeding in a Young Patient with Crohn’s Disease: A Case Report
por: Zeng, Jing, et al.
Publicado: (2022)

Tracheobronchitis in ulcerative colitis: a case report of therapeutic response with infliximab and review of the literature
por: Horgan, Lisa, et al.
Publicado: (2019)

Alopecia universalis during treatment with leflunomide and adalimumab - Case report()
por: Lazzarini, Rosana, et al.
Publicado: (2014)

Adalimumab: Disseminated Mycobacterium tuberculous pericardial tamponade: case report
Publicado: (2021)

Dramatic Response of Nail Psoriasis to Infliximab
por: Safa, Gilles, et al.
Publicado: (2011)

Dramatic response to infliximab in refractory neurosarcoidosis
por: Chintamaneni, Sreekanth, et al.
Publicado: (2010)

Proactive Drug Monitoring Is Associated With Higher Persistence to Infliximab and Adalimumab Treatment and Lower Healthcare Utilization Compared With Reactive and Clinical Monitoring
por: Syed, Nauroz, et al.
Publicado: (2020)

Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
por: Carlsen, Arne, et al.
Publicado: (2018)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Efficacy of infliximab and adalimumab therapy in very early onset, severe ulcerative colitis
por: Rohani, Pejman, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dg3ai93einsd2pklm4se328cbj